Rapid Diagnostic Testing for SARS-CoV-2

The new england journal of medicine
Clinical Practice
Caren G. Solomon, M.D., M.P.H., Editor

Paul K. Drain, M.D., M.P.H.
This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the author’s clinical recommendations.
A 38-year-old woman with type 2 diabetes has a telemedicine visit after learning that a person with whom she had close contact at an indoor wedding 3 days earlier has tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The woman reports that she is asymptomatic and received a second vaccination against SARS-CoV-2 approximately 9 months ago but has not received a booster vac- cination. She attended the wedding with her husband, who has also received two vaccinations, and her two unvaccinated children, who are 5 and 8 years of age. Her husband had mild nasal congestion and a cough the evening before her appointment. She had previously purchased rapid diagnostic tests that received emergency use authorization from the Food and Drug Administration for home-based SARS-CoV-2 testing and wonders whether using these tests would be appropriate. What would you advise?
The Clinical Problem
Approximately 300 million cases of confirmed severe acute re- spiratory syndrome coronavirus 2 (SARS-CoV-2) infection and 5.5 million deaths from coronavirus disease 2019 (Covid-19) have been reported to the World Health Organization (WHO).1 SARS-CoV-2 testing has been critical in identi- fying cases of Covid-19, reducing transmission, and informing public health infec- tion-control measures.2 However, limited access to diagnostic testing in under- served communities and incomplete reporting of Covid-19 data to the WHO3 mean that official numbers, although staggering, probably represent a fraction of total infections and deaths from the Covid-19 pandemic.4,5
Globally, clinical laboratories have performed approximately 3 billion molecular diagnostic tests for SARS-CoV-2.3 The United States has performed more than 600 million tests (2.0 tests per person), which is more in absolute terms than any other country, although China has not reported complete testing data.3 However, total per capita testing rates have been higher across Europe, including the United Kingdom, Denmark, and Austria (4.8, 8.2, and 12.3 tests per person, respectively).3 Performance of high volumes of nucleic acid amplification tests (NAATs) is techni- cally challenging, labor intensive, reliant on efficient specimen transport and re- porting systems, and expensive, all of which contribute to inequitable access to testing.6
During the past several decades, rapid diagnostic tests (RDTs) such as urine tests to detect human chorionic gonadotropin and tests to detect human immu- nodeficiency virus have been increasingly used across health care settings and in
n engl j med nejm.org
The New England Journal of Medicine
Downloaded from nejm.org on January 19, 2022. For personal use only. No other uses without permission. Copyright © 2022 Massachusetts Medical Society. All rights reserved.
From the Departments of Global Health and Medicine, University of Washington, Seattle. Dr. Drain can be contacted at pkdrain@uw.edu or at the International Clinical Research Center, 325 9th Ave., Harborview Medical Center, Box 359927, Seattle, WA 98104-2499.
This article was published on January 7, 2022, at NEJM.org.
DOI: 10.1056/NEJMcp2117115
Copyright © 2022 Massachusetts Medical Society.
1

The new england journal of medicine
Key Clinical Points
Rapid Diagnostic Testing for SARS-CoV-2
• Rapid diagnostic tests (RDTs) that are authorized by the Food and Drug Administration to diagnose severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are either nucleic acid amplification tests to detect genes or antigen-based immunoassays to detect proteins of SARS-CoV-2.
• RDTs are approved for use in persons with symptoms of coronavirus disease 2019 (Covid-19) and in asymptomatic persons who are close contacts of a person with Covid-19 or who have been in a potential high-risk transmission setting.
• Symptomatic persons should undergo testing as soon as possible, quarantine while awaiting test results, and consider retesting if they have a negative RDT, particularly if they have a high pretest probability of infection.
• Asymptomatic persons with a known exposure to SARS-CoV-2 should undergo testing 5 to 7 days after exposure, and if the RDT is negative, they should undergo testing again 2 days later.
• Persons with a known exposure to SARS-CoV-2 who are not fully vaccinated should quarantine while awaiting test results, and persons who test positive should isolate, contact a health care provider or public health department, and inform close contacts about the infection.
2
both high- and low-resource environments. These tests have facilitated diagnosis and treat- ment and reduced reliance on laboratory infra- structure.7 The National Institutes of Health and other funding agencies began supporting the research and development of new diagnostic tests early in the Covid-19 pandemic, and diag- nostic companies prioritized the production of both molecular-based and antigen-based RDTs for SARS-CoV-2.
More than 1000 types of molecular and anti- gen-based immunoassay tests to detect SARS- CoV-2, including at least 400 RDTs, are now commercially available worldwide.8 RDTs are widely available for over-the-counter purchase in Europe, but they have been more difficult to obtain in the United States and in low- and middle-income countries.9 In December 2021, the Biden administration announced plans to purchase 500 million rapid, at-home tests, with the initial delivery starting in January 2022, and to continue using the Defense Production Act to increase both laboratory-based and rapid diag- nostic testing.9 Although RDTs for SARS-CoV-2 are currently in short supply, they are expected to become more widely available in clinic-, com- munity-, and home-based settings, and there is a growing need to understand their clinical indi- cations and interpretation.
Strategies and Evidence
Clinical Course and Diagnostic Testing
The pathophysiology of acute SARS-CoV-2 infec- tion, the clinical course of Covid-19, and the host
n engl j med
immunologic response provide a basis for diag- nostic testing strategies (Fig. 1).10,11 SARS-CoV-2 is predominantly a respiratory airway pathogen, and transmission occurs largely through inhala- tion of small droplets and aerosols.12 Novel ge- nomic viral variants, including the B.1.617.2 (delta) variant, have higher transmissibility than the original D614G virus, leading to faster dis- semination within populations, but they share the same pathophysiology of infection and dis- ease. The WHO recently named the B.1.1.529 (omicron) variant as the sixth “variant of con- cern,” and available evidence suggests it is more transmissible but less virulent than previous variants.
Symptoms of Covid-19 (Table 1) appear 2 to 14 days after exposure, with an average onset 5 to 6 days after infection.13,14 Most persons with Covid-19 have mild-to-moderate symptoms and recover at home, but some, particularly older or unvaccinated adults and those with underlying medical conditions or immunocompromise, may have serious illness.13 SARS-CoV-2 infection also occurs without causing symptoms or Covid-19, and asymptomatic persons can contribute to vi- ral transmission.15-17 Humoral immunity wanes after initial vaccination,18 but booster immuniza- tions have been shown to reduce the incidence of adverse outcomes.19 Viral load levels and clear- ance may be similar among vaccinated and un- vaccinated adults,20 and adults who have not re- ceived a booster immunization have a higher risk of Covid-19–related hospitalization or death than those who have received one.21
Three common indications for diagnostic
nejm.org
The New England Journal of Medicine
Downloaded from nejm.org on January 19, 2022. For personal use only. No other uses without permission. Copyright © 2022 Massachusetts Medical Society. All rights reserved.

SARS-CoV-2 testing, as recommended by the WHO22 and the Centers for Disease Control and Prevention (CDC),23 range from high to low pre- test probability of infection (Fig. 2). First, anyone with Covid-19 symptoms, regardless of vaccina- tion status, should undergo testing for SARS- CoV-2. Second, asymptomatic persons, regardless of vaccination status, who are close contacts of someone with known or probable SARS-CoV-2 infection should undergo diagnostic testing. Per- sons who are unvaccinated or who have not received a vaccine booster within the previous 6 months have a higher pretest probability of infection than those who are fully vaccinated, whereas others have a low or moderate pretest probability of infection. Third, testing should be considered in asymptomatic persons who have been in a setting where the risk of transmission is high, such as in an airplane or at a sporting event. Use of an RDT may also be considered in persons who plan to be in a group setting, even though they may have a low pretest probability of infection; this testing should occur as close to the time of the gathering as possible.
n engl j med
Diagnostic testing for acute SARS-CoV-2 in- fection can be performed with either molecular NAATs or antigen-based assays, and both are available as RDTs.22,23 Molecular NAATs detect the presence of viral gene targets, including the N, S, and E genes and the open reading frame 1ab (ORF 1ab). Reverse-transcriptase–polymerase- chain-reaction (RT-PCR) assays are the most widely used diagnostic SARS-CoV-2 NAATs world- wide.24 Antigen-based tests, also called immuno- assays, detect domains of the surface proteins, including the nucleocapsid, spike, and receptor- binding domains, that are specific to SARS-CoV-2. Although both techniques are highly specific, NAATs are generally more sensitive than anti- gen-based tests because they amplify target ge- nomic sequences. Tests to detect host IgG or IgM antibodies to SARS-CoV-2 should not be used to diagnose acute infection.
The clinical performance of diagnostic SARS- CoV-2 testing extends beyond pathogen targets such as viral proteins and RNA and includes clinical characteristics (e.g., the patient’s viral load and the time since exposure or symptom
nejm.org 3
Clinical Practice
Presymptomatic stage
Viral antigen
IgG
IgM
Viral RNA
Culturable Virus (correlate of infectiousness)
Positive RT-PCR Test
Positive Antigen Test
High IgG and Total Antibody Titers
Onset 7 14 21 28
of symptoms
Days since Onset of Symptoms
Figure 1. Pathophysiology and Timeline of Viremia, Antigenemia, and Immune Response during Acute SARS-CoV-2 Infection.
In some persons, reverse-transcriptase–polymerase-chain-reaction (RT-PCR) tests can remain positive for weeks or months after initial infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but this positivity rarely indicates replication-competent virus that can result in infection.
The New England Journal of Medicine
Downloaded from nejm.org on January 19, 2022. For personal use only. No other uses without permission. Copyright © 2022 Massachusetts Medical Society. All rights reserved.

4
Symptoms or Signs
Typical symptoms of Covid-19
Fever or chills
Congestion, rhinorrhea
Cough
Fatigue
Loss of taste or smell
Nausea, vomiting
Less common symptoms of Covid-19 Sore throat
Headache
Myalgias, arthralgias
Diarrhea
Rash
Red or irritated eyes
Signs or symptoms of severe Covid-19 Difficulty breathing
Shortness of breath (dyspnea) Persistent chest pain or pressure Confusion
Loss of speech or mobility
Cyanosis

Adapted from the Centers for Disease Control and Preven- tion (CDC)13 and the World Health Organization (WHO).14 This list does not include all possible signs or symptoms of coronavirus disease 2019 (Covid-19).
onset), operational testing attributes (e.g., the specimen type, swab technique, transport condi- tions, and laboratory technique), and analytic test properties (e.g., sample preparation and signal amplification).7,25 Although NAATs are highly sensitive and accurate, they can remain positive for weeks to months after infection.26,27 Viral culture studies suggest that SARS-CoV-2 may be capable of replicating only for 10 to 14 days after symptom onset, so NAATs may detect remnant viral RNA well past the time period of recover- ing replication-competent virus.26,27 Conversely, antigen-based assays remain positive for 5 to 12 days after symptom onset and perform better in persons with a high viral load,28 which correlates with disease severity and death.29 Thus, antigen- based tests may correlate better with replication- competent SARS-CoV-2 than molecular tests and may provide information about potential trans- missibility.30
n engl j med
RDTs for Acute SARS-CoV-2 Infection
The Food and Drug Administration (FDA) and WHO have each conducted an expedited review process to accelerate the temporary approval of diagnostic SARS-CoV-2 tests.31,32 As of December 2021, the FDA had granted emergency use autho- rization (EUA) status to 28 RDTs for the diagno- sis of acute SARS-CoV-2 infection, and more FDA- authorized tests are expected.31 In the European Union, more than 140 different companies have had an antigen-based RDT registered on the “common list” for approved use.33 The molecular and antigen-based RDTs with EUA status have various pathogen targets, detection methods, swabbing sites to obtain specimens, indications for use, and performance characteristics (see Ta- ble S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org).
In order for an RDT to receive temporary ap- proval by the FDA, WHO, and European Union regulatory agencies, it must have at least 80% sensitivity (positive percent agreement) and 98% specificity (negative percent agreement), as com- pared with a reference standard of laboratory- based RT-PCR testing, although the WHO has allowed for specificity of 97% or greater.22,31,32,34 Approval by the FDA is also based on a prospec- tive cohort study involving at least 30 persons with SARS-CoV-2 infection and 30 persons with- out SARS-CoV-2 infection.31 An EUA from the European Union is based on performance data that may be obtained either through a prospec- tive clinical study or through retrospective in vitro laboratory testing.33,34 The regulatory agencies require monitoring and reporting of test perfor- mance with respect to viral variants, although these requirements have not been well enforced; they do not require independent verification of clinical validation data provided by each test manufacturer.31,32,34
For several molecular RDTs that are intended for use in low-complexity settings, the FDA has issued EUA status with a Clinical Laboratory Im- provement Amendments (CLIA) certificate of waiv- er (which can be obtained by community health centers, nursing homes, schools, churches, and other gathering places for collecting specimens and performing testing). Some of these RDTs are also approved for home-based use.31 These molecular RDTs, which use RT-PCR, loop-medi- ated isothermal amplification, or nicking enzyme- assisted amplification to detect the viral RNA of SARS-CoV-2, provide results in 13 to 55 minutes.
nejm.org
Table 1. Symptoms of Covid-19 and Signs or Symptoms of Severe Covid-19.*
The new england journal of medicine
The New England Journal of Medicine
Downloaded from nejm.org on January 19, 2022. For personal use only. No other uses without permission. Copyright © 2022 Massachusetts Medical Society. All rights reserved.

Clinical Practice
Figure 2. Indications and Algorithms for Rapid Diagnostic Tests (RDTs) for SARS-CoV-2.
The Centers for Disease Control and Prevention defines a close contact as a person who was less than 6 feet away for 15 minutes or more over a 24-hour period.13,23 Potential high-risk transmission settings include an air- plane, a concert or sporting event, and a crowded or
poorly ventilated indoor area.13,22,23 Covid-19 denotes coronavirus disease 2019.
A High Pretest Probability of Infection — Any Person with Symptoms of Covid-19, Regardless of Vaccination Status
Undergo RDT
Positive test
Negative test
Confirmed Covid-19
No evidence of infection
Not infected with SARS-CoV-2
Isolate, notify health care providers and contacts, and consider treatment
Repeat test in 2 days if there is a high clinical suspicion or if symptoms worsen
Negative test
B Moderate Pretest Probability of Infection — Asymptomatic Person in Close Contact with a Person with Covid-19, Regardless of Vaccination Status
Undergo RDT
Positive test
Negative test
Confirmed Covid-19
No evidence of infection
Not infected with SARS-CoV-2
Isolate, notify health care providers and contacts, and consider treatment
Repeat test in 2 days or if symptoms develop
Negative test
Monitor symptoms for 14 days after exposure
C Low Pretest Probability of Infection — Asymptomatic Person in a Potential High-Risk Transmission Setting
Undergo RDT
Positive test
Negative test
Repeat test if clinical suspicion of Covid-19 is low or if there is a low prevalence of Covid-19
in the population
Not infected with SARS-CoV-2
Positive test
Negative test
Confirmed Covid-19
No evidence of infection
Isolate, notify health care providers and contacts, and consider treatment
All molecular RDTs are approved for use in symp- tomatic persons, and a few also have approval for the screening of asymptomatic persons.
Similarly, many antigen-based RDTs have re- ceived FDA EUA status for use in settings that have received a CLIA waiver or for home-based use.31 These antigen-based RDTs are immunoas- says that use SARS-CoV-2–specific antibodies to bind viral proteins (mostly nucleocapsid) and generate either a visual or fluorescence signal. Most are lateral-flow assays on a nitrocellulose membrane, whereas others involve the use of thin microfluidic test strips, magnetic beads, or an immunofluorescence readout to enhance pro- tein capture and detection.28 All antigen-based RDTs are approved for use in symptomatic per- sons and provide results in 10 to 30 minutes. Several have EUA status for screening of asymp- tomatic persons; most of these tests are intended to be used twice over a period of 3 days, although a small number with high sensitivity for detect- ing asymptomatic infection are approved for use without serial testing.31,35
Although direct-comparison studies are lim- ited and often retrospective, antigen-based RDTs have a lower sensitivity than molecular RDTs, as compared with a reference standard of laborato- ry-based RT-PCR tests, particularly among per- sons who have a low viral load or no replication- competent virus.36-38 However, antigen-based RDTs can detect infection early in the disease course (within 5 to 7 days after symptom onset) when viral loads are high (i.e., a low RT-PCR cycle threshold); these high viral loads account for most transmissions.39-41 Studies have shown vary- ing degrees of clinical accuracy (sensitivity, 36 to 82%; specificity, approximately 98 to 100%) when various antigen-based RDTs are used for screening asymptomatic persons.35,42,43
Although home-based RDTs broaden the use of testing, they have been shown to be more ac- curate when performed by trained health care providers than by untrained persons.44,45 Persons
n engl j med
nejm.org 5
The New England Journal of Medicine
Downloaded from nejm.org on January 19, 2022. For personal use only. No other uses without permission. Copyright © 2022 Massachusetts Medical Society. All rights reserved.

6
who perform tests at home should carefully fol- low test kit instructions.
Interpretation of Results of Testing and Screening
The appropriate interpretation of RDTs for SARS-CoV-2 testing and screening depends on the clinical indication and the pretest probability of infection (Fig. 2). Among persons with a moderate-to-high pretest probability, which in- cludes symptomatic persons and asymptomatic persons who have had close contact with a per- son with Covid-19, a positive RDT indicates a confirmed SARS-CoV-2 infection. However, RDTs may have false negative results, and repeat test- ing should be considered in cases of high clini- cal suspicion or worsening symptoms and in the serial screening of asymptomatic persons. A sec- ond negative RDT 2 days after the initial test or a negative laboratory-based NAAT would help to rule out SARS-CoV-2 infection. All symptomatic persons and asymptomatic persons who have not been fully vaccinated and who have had expo- sure to an infected contact should quarantine while awaiting test results. Although the stan- dard CDC definition of “full vaccination” has been 2 weeks after the second dose in a two- dose vaccination series, many experts (including this author) propose that the definition should include a booster vaccination in persons who are eligible to receive one.
In persons with a low pretest probability of infection (e.g., asymptomatic persons without a known SARS-CoV-2 exposure), a single negative RDT provides reassurance that SARS-CoV-2 in- fection is unlikely. However, given imperfect speci- ficity, a positive RDT may indicate a false posi- tive result. If there is low clinical suspicion or a low prevalence of Covid-19 in the population, then repeat testing should be performed. A sec- ond positive RDT or positive laboratory-based NAAT would confirm SARS-CoV-2 infection. All asymptomatic persons (vaccinated or unvacci- nated) with potential or known exposure should monitor for symptoms for 14 days.
In persons with exposure to SARS-CoV-2, test- ing is generally not useful in the first 48 hours after exposure, since the virus will not have achieved a sufficient viral load.13 The most ap- propriate window for testing is generally consid- ered to be 5 to 7 days after exposure, which is the average peak of symptoms and viral load.13 Therefore, for a single-test strategy, asymptomat-
n engl j med
ic, exposed persons could use an RDT 5 to 7 days after exposure. For a two-test strategy, which is the FDA-approved indication for most RDTs for asymptomatic screening, a second RDT should be performed 2 days after a negative test. All symptomatic persons should be tested at the onset of symptoms and, if test results are nega- tive, repeat testing should be considered if clini- cal suspicion remains high or symptoms wors- en.13 In persons with low pretest probability of infection who have a positive RDT, a confirma- tory test should be performed promptly.
Routine serial screening strategies with fre- quent testing have been proposed and imple- mented to quickly detect SARS-CoV-2 and reduce transmission.46-50 However, when the population prevalence of SARS-CoV-2 is low, the probability of a false positive RDT increases.51,52
Areas of Uncertainty
The global production, delivery, and implemen- tation of RDTs remain challenging.53 Because RDTs may have the greatest benefit in persons who have limited access to laboratory-based NAATs, diagnostic tests should be made avail- able and affordable for underserved populations. In order to reduce global and national inequali- ties in access to testing, enhanced global coor- dination, streamlined regulatory approvals, and increased funding are needed.
Data are lacking from well-designed imple- mentation studies to ascertain the acceptability, accuracy, and effect of community- or home- based testing on SARS-CoV-2 transmission and Covid-19 outcomes. Data are also lacking as to the best way to integrate diagnostic testing into routine medical and surgical care.54 Although some RDTs appear to perform well in the detec- tion of major viral variants,55 most field-based validation studies were conducted before the emergence of the delta and omicron variants. New viral mutations may directly alter the ge- nomic sequence that is detected by molecular RDTs, and the FDA recently issued warnings about two molecular tests that are not expected to detect the omicron variant.56 Since antigen- based RDTs detect epitopes on the surface pro- teins (mostly nucleocapsid), their performance is more dependent on protein structure and confir- mation than on single genomic mutations. Nonetheless, clinical studies are urgently needed to evaluate the performance of molecular and
nejm.org
The new england journal of medicine
The New England Journal of Medicine
Downloaded from nejm.org on January 19, 2022. For personal use only. No other uses without permission. Copyright © 2022 Massachusetts Medical Society. All rights reserved.

Clinical Practice
Table 2. Summary of Major Guidelines and Recommendations for RDTs to Detect SARS-CoV-2.*
Guideline or Recommendation
Antigen-based RDT
Testing indication
Asymptomatic person with high pretest probability of infection
Specific situation
Confirmatory testing recommended
Provide support for patient performing swab specimen collection
Case registration, isolation, and contact tracing
WHO CDC
Yes Yes
Yes Yes
No No
No Yes
Yes Yes
ECDC IDSA
Yes No
Yes Yes, molecular test only
Yes‡ Yes§
No Yes
Yes NC
Endorsement of RDTs
Molecular RDT
Yes
Yes
Yes
Yes
Person with symptoms of Covid-19
Yes
Yes
Yes
Yes, molecular test only
Screening in asymptomatic person with low pretest probability of infection
Yes†
Yes
Yes, if population prevalence ≥10%
Yes, molecular test only
Repeat serial RDTs after negative test, if high clinical suspicion
Yes†
Yes
Yes
No
Timing for testing an asymptomatic person after an exposure
NC
5–7 days
2–7 days
NC
Endorse home-based RDT
No
Yes
NC
NC

ECDC denotes European Center for Disease Prevention and Control, IDSA Infectious Diseases Society of America, NC no comment in guideline document, RDT rapid diagnostic test, and SARS-CoV-2 severe acute respiratory syndrome coronavirus 2.
† The WHO endorses antigen-based RDTs for serial screening strategies when there is a suspected outbreak of Covid-19 in congregate settings, including schools, nursing homes, and health care facilities, and emphasizes that these tests will be most reliable in settings with ongoing transmission, which they define as a test positivity rate of 5% or higher.22
‡ The ECDC recommends confirmation of all antigen-based RDTs with either a laboratory-based nucleic acid amplifica- tion test (NAAT) or a second different antigen-based RDT.
§ The IDSA recommends confirmation of negative antigen-based RDTs with a laboratory-based NAAT in symptomatic patients who have a high clinical pretest probability of infection.
antigen-based RDTs, including saliva-based tests, in detecting emerging variants of concern. Stud- ies are also needed to evaluate the performance of these tests with respect to breakthrough in- fections among vaccinated persons (with or with- out booster vaccination).
Guidelines
Guidelines from the WHO, CDC, and European Center for Disease Prevention and Control all endorse and recommend the use of RDTs for diagnosis in persons who have symptoms con- sistent with Covid-19 and in the screening of asymptomatic persons who are at high risk for acute SARS-CoV-2 infection.22,23,34 The recommen- dations in this article are generally consistent with these guidelines. On the basis of a very low-to-moderate quality of evidence,57 the Infec- tious Diseases Society of America (IDSA) recom-
n engl j med
mends either a molecular RT-PCR RDT or a laboratory-based NAAT over antigen-based RDTs both for testing of symptomatic persons and for screening of asymptomatic persons. However, the IDSA acknowledges that antigen-based RDTs may be helpful in areas where molecular testing is neither readily available nor feasible. Recom- mended indications for testing and use of RDTs in specific situations are summarized in Table 2.
The woman in the vignette and her family are at moderate risk for acquiring SARS-CoV-2 infec- tion owing to their close contact 3 days previ- ously with a person who was found to have confirmed Covid-19. All family members should be tested for SARS-CoV-2 infection. She has type 2 diabetes, which increases her risk of severe
nejm.org 7
The New England Journal of Medicine
Downloaded from nejm.org on January 19, 2022. For personal use only. No other uses without permission. Copyright © 2022 Massachusetts Medical Society. All rights reserved.
Conclusions and Recommendations

8
illness. If the woman and her children remain asymptomatic, testing is appropriate 5 to 7 days after exposure and can be performed with the use of an RDT that has received FDA EUA status for home-based testing of asymptomatic persons. Quarantine is not currently recommended for asymptomatic persons who have had two vacci- nations and are awaiting test results, but given her unboosted vaccination status and emerging data regarding the omicron variant, I would ad- vise her to minimize contact with others.
If the test is negative, it should be repeated in 2 days with another home test or a laboratory- based NAAT (depending on availability). Close monitoring for symptoms is recommended for 2 weeks after exposure, with quarantine and retesting if symptoms develop.
It appears that the woman’s husband may have symptoms of Covid-19. He should quarantine and be tested promptly with any FDA-approved, home-based RDT. If the test is negative, a sec- ond RDT or laboratory-based NAAT should be considered, particularly if his condition wors- ens. The children’s return to day care or school should be guided by local regulations.
Any persons who have a positive RDT should contact a health care provider or public health department to report their infection and to dis- cuss any symptoms as well as therapy, hospital- ization, or both. According to CDC recommen- dations for persons who test positive, persons who are asymptomatic may discontinue isolation 5 days after a positive test, and those who have symptoms that are resolving (and who are afebrile for 24 hours without the use of antipyretic agents) may discontinue isolation 5 days after a positive test or 5 days after the onset of symptoms, which- ever is later. In these persons, the use of a well- fitted mask in public is recommended for 5 days after the end of the isolation period. In persons who continue to have symptoms or fever, a 10-day isolation period is recommended. Like many other experts, I recommend that all persons have a negative test in order to safely discontinue isola- tion before a full 10 days after a positive test. The patient and her husband should be encouraged to receive booster vaccinations and to vaccinate their children.
Disclosure forms provided by the author are available with the full text of this article at NEJM.org.
References

World Health Organization. WHO coro- navirus (COVID-19) dashboard (https:// covid19.who.int).
Technical specifications for selection of essential in vitro diagnostics for SARS- CoV-2. Geneva: World Health Organiza- tion, April 19, 2021 (https://www.who.int/ publications/m/item/technical-specifications -for-selection-of-essential-in-vitro -diagnostics-for-sars-cov-2).
Ritchie H, Mathieu E, Rodés-Guirao L, et al. Coronavirus pandemic (COVID-19). Our World in Data (https://ourworldindata .org/coronavirus).
Wu SL, Mertens AN, Crider YS, et al. Substantial underestimation of SARS- CoV-2 infection in the United States. Nat Commun 2020;11:4507.
Institute for Health Metrics and Eval- uation. COVID-19 has caused 6.9 million deaths globally, more than double what official reports show. May 6, 2021 (http:// http://www.healthdata.org/news-release/covid-19 -has-caused-69-million-deaths-globally -more-double-what-off icial-reports-show). 6. Yadav H, Shah D, Sayed S, Horton S, Schroeder LF. Availability of essential di- agnostics in ten low-income and middle- income countries: results from national health facility surveys. Lancet Glob Health 2021;9(11):e1553-e1560.
Drain PK, Hyle EP, Noubary F, et al. Diagnostic point-of-care tests in resource-
limited settings. Lancet Infect Dis 2014; 14:239-49.
Foundation for Innovative New Diag- nostics. Test directory (https://www.finddx .org/test-directory/).
The White House. Fact sheet: President Biden announces new actions to protect Americans and help communities and hos- pitals battle omicron. December 21, 2021 (https://www.whitehouse.gov/briefing -room/statements-releases/2021/12/21/fact -sheet-president-biden-announces-new -actions-to-protect-americans-and-help -communities-and-hospitals-battle -omicron/).
He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmis- sibility of COVID-19. Nat Med 2020;26: 672-5.
Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospital- ized patients with COVID-2019. Nature 2020;581:465-9.
Jones TC, Biele G, Mühlemann B, et al. Estimating infectiousness throughout SARS-CoV-2 infection course. Science 2021; 373:eabi5273.
Centers for Disease Control and Pre- vention. Symptoms of COVID-19. February 2021 (https://www.cdc.gov/coronavirus/2019 -ncov/symptoms-testing/symptoms.html). 14. World Health Organization. Corona- virus disease (COVID-19): symptoms
n engl j med nejm.org
(https://www.who.int/health-topics/ coronavirus#tab=tab_3).
Byambasuren O, Cardona M, Bell K, Clark J, McLaws M-L, Glasziou P. Estimat- ing the extent of asymptomatic COVID-19 and its potential for community trans- mission: systematic review and meta- analysis. Off J Assoc Med Microbiol Infect Dis Can 2020;5:223-34.
Qiu X, Nergiz AI, Maraolo AE, Bogoch II, Low N, Cevik M. The role of asymp- tomatic and pre-symptomatic infection in SARS-CoV-2 transmission — a living sys- tematic review. Clin Microbiol Infect 2021; 27:511-9.
Buitrago-Garcia D, Egli-Gany D, Cou- notte MJ, et al. Occurrence and trans- mission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analy- sis. PLoS Med 2020;17(9):e1003346.
Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med 2021;385(24):e84.
Bar-On YM, Goldberg Y, Mandel M, et al. Protection against Covid-19 by BNT162b2 booster across age groups. N Engl J Med 2021;385:2421-30.
Kissler SM, Fauver JR, Mack C, et al. Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated persons. N Engl J Med 2021;385:2489-91.
The new england journal of medicine
The New England Journal of Medicine
Downloaded from nejm.org on January 19, 2022. For personal use only. No other uses without permission. Copyright © 2022 Massachusetts Medical Society. All rights reserved.
Arbel R, Hammerman A, Sergienko R, et al. BNT162b2 vaccine booster and mortality due to Covid-19. N Engl J Med 2021;385:2413-20.
World Health Organization. Antigen- detection in the diagnosis of SARS-CoV-2 infection. Interim guidance. October 6, 2021 (https://www.who.int/publications/i/ item/antigen-detection-in-the-diagnosis -of-sars-cov-2infection-using-rapid -immunoassays).
Centers for Disease Control and Pre- vention. Testing for COVID-19. October 4, 2021 (https://www.cdc.gov/coronavirus/ 2019-ncov/testing/index.html).
European Commission Joint Research Center. COVID-19 in vitro diagnostic med- ical devices (https://covid-19-diagnostics .jrc.ec.europa.eu/devices?device_id= &manufacturer=&text_name=&marking= Yes&method=&rapid_diag=1&target_type= 6&search_method=AND#form_content). 25. Mina MJ, Andersen KG. COVID-19 testing: one size does not fit all. Science 2021;371:126-7.
Bullard J, Dust K, Funk D, et al. Pre- dicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples. Clin Infect Dis 2020;71:2663-6. 27. Lee S, Kim T, Lee E, et al. Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a commu- nity treatment center in the Republic of Korea. JAMA Intern Med 2020;180:1447-52. 28. Drain PK, Ampajwala M, Chappel C, et al. A rapid, high-sensitivity SARS-CoV-2 nucleocapsid immunoassay to aid diagno- sis of acute COVID-19 at the point of care: a clinical performance study. Infect Dis Ther 2021;10:753-61.
Fajnzylber J, Regan J, Coxen K, et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun 2020;11:5493.
Pekosz A, Parvu V, Li M, et al. Antigen- based testing but not real-time polymerase chain reaction correlates with severe acute respiratory syndrome coronavirus 2 viral culture. Clin Infect Dis 2021;73(9):e2861- e2866.
Food and Drug Administration. Emer- gency use authorizations for medical de- vices. 2021 (https://www.fda.gov/medical -devices/emergency-situations-medical -devices/emergency-use-authorizations -medical-devices#covid19ivd).
World Health Organization. Emer- gency use listing procedure for in vitro diagnostics. 2020 (https://www.who.int/ teams/regulation-prequalification/eul/in -vitro-emergency-use-listing-procedure). 33. European Commission Directorate- General for Health and Food Safety. EU health preparedness: a common list of COVID-19 rapid antigen tests; a common standardised set of data to be included in COVID-19 test result certificates; and a common list of COVID-19 laboratory based antigenic assays. December 2021 (https://
ec.europa.eu/health/sites/default/files/ preparedness_response/docs/covid-19_rat _common-list_en.pdf).
European Centre for Disease Preven- tion and Control. Options for the use of rapid antigen tests for COVID-19 in the EU/EEA — first update. October 26, 2021 (https://www.ecdc.europa.eu/en/ publications-data/options-use-rapid-antigen -tests-covid-19-eueea-first-update).
Drain P, Sulaiman R, Hoppers M, Lindner NM, Lawson V, Ellis JE. Perfor- mance of the LumiraDx Microf luidic Im- munof luorescence Point-of-Care SARS- CoV-2 Antigen Test in asymptomatic adults and children. Am J Clin Pathol 2021 October 20 (Epub ahead of print). 36. Corman VM, Haage VC, Bleicker T, et al. Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evalua- tion study. Lancet Microbe 2021;2(7): e311-e319.
Jääskeläinen AE, Ahava MJ, Jokela P, et al. Evaluation of three rapid lateral flow antigen detection tests for the diagnosis of SARS-CoV-2 infection. J Clin Virol 2021;137:104785.
Lindner AK, Krüger LJ, Nikolai O, et al. SARS-CoV-2 variant of concern B.1.1.7: di- agnostic accuracy of three antigen-detect- ing rapid tests. June 15, 2021 (https://www .medrxiv.org/content/10.1101/2021.06.15 .21258502v1). preprint.
Brümmer LE, Katzenschlager S, Gaed- dert M, et al. Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living systematic review and meta-analysis. PLoS Med 2021;18(8):e1003735.
Dinnes J, Deeks JJ, Berhane S, et al. Rapid, point-of-care antigen and molecu- lar-based tests for diagnosis of SARS- CoV-2 infection. Cochrane Database Syst Rev 2021;3:CD013705.
Lee J, Song J-U, Shim SR. Comparing the diagnostic accuracy of rapid antigen detection tests to real time polymerase chain reaction in the diagnosis of SARS- CoV-2 infection: a systematic review and meta-analysis. J Clin Virol 2021;144:104985. 42. Prince-Guerra JL, Almendares O, Nolen LD, et al. Evaluation of Abbott BinaxNOW rapid antigen test for SARS-CoV-2 infec- tion at two community-based testing sites — Pima County, Arizona, November 3–17, 2020. MMWR Morb Mortal Wkly Rep 2021;70:100-5.
Pray IW, Ford L, Cole D, et al. Perfor- mance of an antigen-based test for asymp- tomatic and symptomatic SARS-CoV-2 testing at two university campuses — Wisconsin, September–October 2020. MMWR Morb Mortal Wkly Rep 2021;69: 1642-7.
Frediani JK, Levy JM, Rao A, et al. Multidisciplinary assessment of the Ab- bott BinaxNOW SARS-CoV-2 point-of-care antigen test in the context of emerging viral variants and self-administration. Sci Rep 2021;11:14604.
n engl j med nejm.org
Lindner AK, Nikolai O, Kausch F, et al. Head-to-head comparison of SARS- CoV-2 antigen-detecting rapid test with self-collected nasal swab versus profes- sional-collected nasopharyngeal swab. Eur Respir J 2021;57:2003961.
Mina MJ, Parker R, Larremore DB. Rethinking COVID-19 test sensitivity — a strategy for containment. N Engl J Med 2020;383(22):e120.
Larremore DB, Wilder B, Lester E, et al. Test sensitivity is secondary to fre- quency and turnaround time for COVID-19 screening. Sci Adv 2021;7:eabd5393.
Love N, Ready D, Turner C, et al. The acceptability of testing contacts of con- firmed COVID-19 cases using serial, self- administered lateral f low devices as an alternative to self-isolation. March 26, 2021 (https://www.medrxiv.org/content/10.1101/ 2021.03.23.21254168v1). preprint.
Pavelka M, Van-Zandvoort K, Abbott S, et al. The impact of population-wide rapid antigen testing on SARS-CoV-2 prevalence in Slovakia. Science 2021;372: 635-41.
Young BC, Eyre DW, Kendrick S, et al. Daily testing for contacts of individuals with SARS-CoV-2 infection and atten- dance and SARS-CoV-2 transmission in English secondary schools and colleges: an open-label, cluster-randomised trial. Lancet 2021;398:1217-29.
Martín-Sánchez V, Fernández-Villa T, Carvajal Urueña A, et al. Role of rapid an- tigen testing in population-based SARS- CoV-2 screening. J Clin Med 2021;10: 3854.
Ricks S, Kendall EA, Dowdy DW, Sacks JA, Schumacher SG, Arinaminpathy N. Quantifying the potential value of anti- gen-detection rapid diagnostic tests for COVID-19: a modelling analysis. BMC Med 2021;19:75.
Peeling RW, Olliaro PL, Boeras DI, Fongwen N. Scaling up COVID-19 rapid antigen tests: promises and challenges. Lancet Infect Dis 2021;21(9):e290-e295. 54. Drain PK, Garrett N. SARS-CoV-2 pandemic expanding in sub-Saharan Af- rica: considerations for COVID-19 in peo- ple living with HIV. EClinicalMedicine 2020;22:100342.
Bekliz M, Adea K, Essaidi-Laziosi M, et al. SARS-CoV-2 rapid diagnostic tests for emerging variants. Lancet Microbe 2021;2(8):e351.
Food and Drug Administration. SARS- CoV-2 viral mutations: impact on COVID-19 tests. 2021 (https://www.fda.gov/medical -devices/coronavirus-covid-19-and-medical -devices/sars-cov-2-viral-mutations-impact -covid-19-tests).
Hanson KE, Altayar O, Caliendo AM, et al. IDSA guidelines on the diagnosis of COVID-19: antigen testing. Arlington, VA: Infectious Diseases Society of Amer- ica, May 27, 2021 (www.idsociety.org/ COVID19guidelines/Ag).
Copyright © 2022 Massachusetts Medical Society.
Clinical Practice
The New England Journal of Medicine
Downloaded from nejm.org on January 19, 2022. For personal use only. No other uses without permission. Copyright © 2022 Massachusetts Medical Society. All rights reserved.
9